自拟补肺益气化瘀汤治疗气血瘀滞型晚期非小细胞肺癌的效果及对免疫炎症水平的影响  

Efficacy of self-prescribed Bufei Yiqi Huayu Decoction in treating advanced non-small cell lung cancer with Qi-stagnation and blood-stasis syndrome and its impact on immune-inflammatory levels

作　　者：付亚丽 马天江[1] 刘朵平 曹艳娇 FU Ya-li;MATian-jiang;LIU Duo-ping;CAO Yan-jiao(Department of Oncology,Luohe Central Hospital,Luohe 462000,Henan,CHINA)

机构地区：[1]漯河市中心医院肿瘤科,河南漯河462000

出　　处：《海南医学》2025年第5期639-643,共5页Hainan Medical Journal

基　　金：2021年度河南省医学科技攻关计划联合共建项目(编号:LHQI202109610)。

摘　　要：目的 探讨自拟补肺益气化瘀汤治疗气血瘀滞型晚期非小细胞肺癌(NSCLC)的效果及对免疫炎症水平的影响。方法 前瞻性选取2022年2月至2023年12月漯河市中心医院收治的124例气血瘀滞型晚期NSCLC患者作为研究对象,按随机数表法分为对照组和研究组各62例。对照组患者采用盐酸安罗替尼治疗,研究组患者采用盐酸安罗替尼联合自拟补肺益气化瘀汤治疗,3周为一个疗程,两组患者均治疗两个疗程。治疗后,比较两组患者的临床效果,以及治疗前及治疗后的中医症候积分(包括神疲乏力、气短胸闷、胸部刺痛和脉络瘀血的中医证候积分)和免疫炎症因子水平[白细胞介素-6 (IL-6)、免疫球蛋白A (IgA)];同时比较两组患者治疗期间的不良反应发生情况。结果 治疗后,研究组患者的临床总有效率为62.90%,明显高于对照组的41.94%,差异有统计学意义(P<0.05);治疗前,两组患者的中医症候积分比较差异无统计学意义(P>0.05),治疗后,研究组患者的神疲乏力、气短胸闷、胸部刺痛、脉络瘀血的中医证候积分分别为(1.55±0.18)分、(1.62±0.17)分、(1.50±0.15)分、(1.75±0.12)分,明显低于对照组的(2.31±0.32)分、(2.90±0.25)分、(2.73±0.30)分、(2.61±0.20)分,差异均有统计学意义(P<0.05);治疗前,两组患者的IL-6水平、Ig A水平比较差异均无统计学意义(P>0.05),治疗后,研究组患者的IL-6水平为(33.90±4.83) ng/L,明显低于对照组的(39.68±5.92) ng/L,IgA水平为(3.30±0.61) g/L,明显高于对照组的(2.69±0.53) g/L,差异均有统计学意义(P<0.05);治疗期间研究组患者的不良反应总发生率为12.90%,略高于对照组的9.68%,但差异无统计学意义(P>0.05)。结论 自拟补肺益气化瘀汤治疗气血瘀滞型晚期NSCLC患者能有效抑制肿瘤进展,调节免疫炎症水平,且不良反应少。Objective To evaluate the efficacy of self-prescribed Bufei Yiqi Huayu Decoction in treating advanced non-small cell lung cancer(NSCLC)with Qi-stagnation and blood-stasis syndrome and its impact on immune-inflammatory levels.Methods A prospective study included 124 patients of advanced NSCLC with Qi-stagnation and blood-stasis syndrome admitted to Luohe Central Hospital from February 2022 to December 2023.Patients were randomized into a control group(n=62)and a study group(n=62).The patients in the control group received anlotinib hydrochloride,while those in the study group received anlotinib hydrochloride combined with self-prescribed Bufei Yiqi Huayu Decoction.Both groups were treated for two cycles(3 weeks per cycle).The clinical efficacy after treatment,traditional Chinese medicine(TCM)symptom scores(fatigue,shortness of breath,chest pain,and blood stasis)and immune-inflammatory markers(interleukin-6[IL-6],immunoglobulin A[IgA])before and after treatment,and adverse events during treatment were compared between the two groups.Results After treatment,the study group showed a significantly higher clinical efficacy rate(62.90%vs 41.94%,P<0.05).Before treatment,there was no statistically significant difference in the TCM symptom scores between the two groups(P>0.05).After treatment,TCM symptom scores for fatigue,shortness of breath,chest pain,and blood stasis were(1.55±0.18)points,(1.62±0.17)points,(1.50±0.15)points,and(1.75±0.12)points,significantly lower(2.31±0.32)points,(2.90±0.25)points,(2.73±0.30)points,and(2.61±0.20)points in the study group(P<0.05).Before treatment,there was no statistically significant difference in IL-6 and IgA levels between the two groups(P>0.05).After treatment,IL-6 levels were significantly lower and IgA levels were significantly higher in the study group:(33.90±4.83)ng/L vs(39.68±5.92)ng/L,P<0.05;(3.30±0.61)g/L vs(2.69±0.53)g/L,P<0.05.The incidence of adverse events was slightly higher in the study group (12.90% vs 9.68%), but the difference was not statistically signif

关 键 词：非小细胞肺癌 晚期 气血瘀滞型 自拟补肺益气化瘀汤 免疫炎症 疗效 

分 类 号：R734.2[医药卫生—肿瘤]